A disease most Americans thought was beaten is quietly rebounding—while Washington’s attention and budgets are tied up elsewhere.
Quick Take
- U.S. tuberculosis cases climbed after COVID-era disruptions, reaching 10,388 cases in 2024, with high-risk groups hit hardest.
- Public-health agencies warn that missed diagnoses and delayed treatment have helped TB regain ground, especially in congregate settings like jails and prisons.
- Drug-resistant TB remains a central concern because treatment is long, multi-drug, and costly when systems fail to catch cases early.
- New York City reported an 11% drop in cases in 2025 compared with 2024, but officials say elevated risk persists.
TB’s return exposes a basic vulnerability at home
U.S. tuberculosis is rising from a low baseline, and the post-pandemic bump is now hard to ignore. Preliminary reporting tied to COVID-19-era disruptions points to missed diagnoses and treatment delays that enabled transmission and the accumulation of late-stage illness.
Nationally, 2024 recorded 10,388 TB cases. Health officials emphasize that TB is airborne and typically chronic, demanding sustained follow-up rather than a one-and-done prescription.
'White plague' is on the rise in the US – it's deadlier than Covid and becoming antibiotic resistant https://t.co/RbrjT2kbyJ pic.twitter.com/nD0UC5lwm8
— New York Post (@nypost) March 25, 2026
The term “white plague” is historical, but the modern reality is clinical and logistical: patients often require multiple antibiotics for four to six months, and adherence matters for both individual cure and preventing resistance. Experts also stress that U.S. TB is not evenly distributed.
Cases disproportionately cluster among people facing poverty, limited access to primary care, and higher exposure risk, including incarcerated populations and some immigrant communities.
Why the post-COVID years made TB harder to control
COVID-19 did not cause tuberculosis, but it disrupted the detection and treatment pipeline that keeps TB contained. When routine care, screening, and in-person evaluations fell off from 2020 through 2023, latent TB infections were less likely to be found and treated before becoming active disease.
That gap matters because TB spreads through the air and can simmer for long periods, especially when people delay care or cannot access it.
Americas-wide data reinforce the scale of the challenge beyond U.S. borders: in 2024, the region was estimated to have about 350,000 TB illnesses and about 30,000 deaths, with a large number of cases going undiagnosed.
Public-health officials also flag HIV coinfection as a complicating factor, with a significant share of TB deaths in the Americas occurring among people living with HIV. Those trends raise the stakes for better screening and reliable treatment completion.
Drug resistance and long treatment make failures expensive
Drug-resistant TB is not a talking point; it is a predictable outcome when treatment is interrupted, mismanaged, or inaccessible. Clinicians describe standard TB therapy as effective but burdensome: patients can face three to four antibiotics over months, with side effects and practical barriers that derail compliance.
When the system loses track of patients—or when social conditions make follow-up unrealistic—resistance becomes more likely and outbreaks become harder to stop.
Researchers also connect TB spread to the environments where people live and work. Congregate settings like shelters and correctional facilities can amplify transmission when ventilation, screening, and rapid isolation protocols are weak.
Some experts are studying how genomics can help map transmission chains and how factors like air pollution may worsen respiratory vulnerability. The through-line is simple: TB control depends on basic capacity—testing, tracing, and finishing treatment.
Local progress is real, but it does not erase national risk
New York City provides an example of mixed signals that can confuse the public. The city reported an 11% decrease in TB cases in 2025 compared with 2024, yet officials still describe TB as a continuing concern.
That is consistent with how outbreaks work: one jurisdiction can improve while national totals rise, particularly if transmission concentrates in specific high-risk communities or settings where compliance and access are hardest to maintain.
NEWS🚨: 'White plague' is on the rise in the US – it's deadlier than Covid and becoming antibiotic resistant, says NYP pic.twitter.com/hHoZ4EHqZP
— All day Astronomy (@forallcurious) March 25, 2026
World Tuberculosis Day messaging in 2026 emphasized primary care access, faster diagnostics, and people-centered treatment.
That approach is practical, but it also collides with a political reality many conservative voters are feeling in 2026: the federal government can move mountains abroad, yet Americans still struggle to get timely, straightforward healthcare at home. Limited data in public summaries makes it hard to quantify the 2025–2026 national trajectory, but the warning lights are clear.
Sources:
The Resurgence of Tuberculosis in the United States
The Resurgence of Tuberculosis in the United States
World Tuberculosis Day: What You Should Know (2026)
World Tuberculosis Day 2026 (NYC Health press page)
